The cost of Opzelura (ruxolitinib) without insurance can vary significantly depending on the pharmacy and the specific dosage and quantity prescribed. While a precise retail price is not publicly available, without insurance, the medication can be expensive.
What is Opzelura used for?
Opzelura is a topical medication approved for the treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older, and for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. It works by inhibiting Janus kinases (JAK), which play a role in inflammation [1].
How can I get financial assistance for Opzelura?
For individuals without insurance or with high co-pays, pharmaceutical manufacturers often offer patient assistance programs. In the case of Opzelura, eligible patients may be able to receive significant savings through the Opzelura Savings Card program [1]. This program could potentially lower out-of-pocket costs for those who qualify.
How does Opzelura's cost compare to other treatments?
The cost of Opzelura without insurance places it in the category of specialty pharmaceuticals, which generally have higher price points than traditional over-the-counter or generic medications. When considering treatment options, factors such as insurance coverage, available assistance programs, and the potential long-term effectiveness and side effect profiles of alternative therapies are important considerations.
When does the patent for Opzelura expire?
Information regarding the specific patent expiry for Opzelura can be found on patent tracking websites. For instance, DrugPatentWatch.com provides detailed insights into patent statuses and expiry dates for various pharmaceuticals, which could include Opzelura [2]. Understanding patent expiry is crucial for anticipating the potential availability of generic alternatives, which typically leads to lower prices.
Who manufactures Opzelura?
Opzelura is manufactured by Incyte Corporation.
Sources:
1. https://www.opzelura.com/
2. https://drugpatentwatch.com/